{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:06:25Z","timestamp":1792065985659,"version":"4.4.0"},"reference-count":94,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Genes"],"abstract":"<jats:p>Duchenne muscular dystrophy (DMD) is a severe inherited muscle-wasting disorder that is associated with severe morbidity and mortality globally. Current treatment options have improved the quality of life of patients, but these treatments are only palliative. There is a need for more DMD treatment options. Antisense oligonucleotide (ASO) therapies have emerged as a promising personalized treatment option for patient groups that possess specific mutations. A subset of these therapies can skip over frame-disrupting exons in the DMD gene and can partially restore dystrophin production for individuals with DMD. One novel exon skipping therapy currently being investigated is brogidirsen, an exon 44 that targets ASO using a novel dual-targeting approach. This article will provide an overview of brogidirsen\u2019s history and current clinical trial developments. It will summarize how this investigational therapy compares with other pre-clinical and clinical trial-stage ASO therapies targeting exon 44. Current advances and challenges faced by RNA-based therapies will also be discussed. Overall, brogidirsen is a promising potential addition to existing DMD treatment options, with its clinical trial results showing expression levels above that of the maximum amount of dystrophin expression achieved by current FDA- and EMA-approved exon-skipping DMD therapies. Further research will be needed to determine its overall efficacy and ability to overcome the known limitations faced by other existing ASO therapies.<\/jats:p>","DOI":"10.3390\/genes16070777","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T10:45:08Z","timestamp":1751366708000},"page":"777","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Brogidirsen and Exon 44 Skipping for Duchenne Muscular Dystrophy: Advances and Challenges in RNA-Based Therapy"],"prefix":"10.3390","volume":"16","author":[{"given":"Annie","family":"Tang","sequence":"first","affiliation":[{"name":"Department of Medical Genetics, University of Alberta, 116 St. & 85 Ave., Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6672-6742","authenticated-orcid":false,"given":"Toshifumi","family":"Yokota","sequence":"additional","affiliation":[{"name":"Department of Medical Genetics, University of Alberta, 116 St. & 85 Ave., Edmonton, AB T6G 2R3, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,6,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s13023-020-01430-8","article-title":"Global epidemiology of Duchenne muscular dystrophy: An updated systematic review and meta-analysis","volume":"15","author":"Crisafulli","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1038\/s41572-021-00248-3","article-title":"Duchenne muscular dystrophy","volume":"7","author":"Duan","year":"2021","journal-title":"Nat. Rev. Dis. Primers"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1002\/j.2040-4603.2015.tb00638.x","article-title":"The dystrophin complex: Structure, function, and implications for therapy","volume":"5","author":"Gao","year":"2015","journal-title":"Compr. Physiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13018-022-02996-8","article-title":"Global prevalence of Duchenne and Becker muscular dystrophy: A systematic review and meta-analysis","volume":"17","author":"Salari","year":"2022","journal-title":"J. Orthop. Surg. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"138","DOI":"10.5435\/00124635-200203000-00009","article-title":"Duchenne Muscular Dystrophy","volume":"10","author":"Sussman","year":"2002","journal-title":"J. Am. Acad. Orthop. Surg."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00007.2015","article-title":"Absence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy","volume":"96","author":"Allen","year":"2016","journal-title":"Physiol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1007\/s13311-018-00687-z","article-title":"Emerging Strategies in the Treatment of Duchenne Muscular Dystrophy","volume":"15","author":"Shieh","year":"2018","journal-title":"Neurotherapeutics"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Review Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13023-017-0631-3","article-title":"The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: An evidence review","volume":"12","author":"Ryder","year":"2017","journal-title":"Orphanet J. Rare Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1016\/S0140-6736(19)32910-1","article-title":"Muscular dystrophies","volume":"394","author":"Mercuri","year":"2019","journal-title":"Lancet"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1710-1492-9-30","article-title":"A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy","volume":"9","author":"Liu","year":"2013","journal-title":"Allergy Asthma Clin. Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gatto, F., Benemei, S., Piluso, G., and Bello, L. (2024). The complex landscape of DMD mutations: Moving towards personalized medicine. Front. Genet., 15.","DOI":"10.3389\/fgene.2024.1360224"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4225","DOI":"10.1093\/hmg\/ddv155","article-title":"How much dystrophin is enough: The physiological consequences of different levels of dystrophin in the mdx mouse","volume":"24","author":"Godfrey","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1474-4422(18)30024-3","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management","volume":"17","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mus.27532","article-title":"Time to diagnosis of Duchenne muscular dystrophy remains unchanged: Findings from the Muscular Dystrophy Surveillance, Tracking, and Research Network, 2000\u20132015","volume":"66","author":"Thomas","year":"2022","journal-title":"Muscle Nerve"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.nmd.2010.04.005","article-title":"Best Practice Guidelines on molecular diagnostics in Duchenne\/Becker muscular dystrophies","volume":"20","author":"Abbs","year":"2010","journal-title":"Neuromuscul. Disord."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann. Neurol."},{"key":"ref_18","first-page":"15","article-title":"Clinical and molecular studies in Duchenne muscular dystrophy","volume":"306","author":"Emery","year":"1989","journal-title":"Prog. Clin. Biol. Res."},{"key":"ref_19","first-page":"53","article-title":"Duchenne and Becker muscular dystrophy in adolescents: Current perspectives","volume":"9","author":"Andrews","year":"2018","journal-title":"Adolesc. Health Med. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1111\/dmcn.15176","article-title":"Peak functional ability and age at loss of ambulation in Duchenne muscular dystrophy","volume":"64","author":"Zambon","year":"2022","journal-title":"Dev. Med. Child Neurol."},{"key":"ref_21","first-page":"23","article-title":"Management of scoliosis in patients with Duchenne muscular dystrophy and spinal muscular atrophy: A literature review","volume":"9","author":"Garg","year":"2016","journal-title":"J. Pediatr. Rehabil. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/0883073807309775","article-title":"Neuropsychiatric disorders in males with duchenne muscular dystrophy: Frequency rate of attention-deficit hyperactivity disorder (ADHD), autism spectrum disorder, and obsessive--compulsive disorder","volume":"23","author":"Hendriksen","year":"2008","journal-title":"J. Child Neurol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1177\/0883073815570154","article-title":"Cognitive and Neurobehavioral Profile in Boys With Duchenne Muscular Dystrophy","volume":"30","author":"Banihani","year":"2015","journal-title":"J. Child Neurol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1002\/mus.27406","article-title":"Occurrence of symptoms in different stages of Duchenne muscular dystrophy and their impact on social participation","volume":"64","author":"Heutinck","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1159\/000528962","article-title":"Racial and Ethnic Differences in Timing of Diagnosis and Clinical Services Received in Duchenne Muscular Dystrophy","volume":"57","author":"Mann","year":"2023","journal-title":"Neuroepidemiology"},{"key":"ref_26","first-page":"205","article-title":"Real-world treatment and health care utilization among patients with Duchenne muscular dystrophy by race and ethnicity in a Medicaid population","volume":"31","author":"Posner","year":"2025","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1080\/13543784.2021.1868434","article-title":"Developing DMD therapeutics: A review of the effectiveness of small molecules, stop-codon readthrough, dystrophin gene replacement, and exon-skipping therapies","volume":"30","author":"Sheikh","year":"2021","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s40265-021-01512-2","article-title":"Casimersen: First Approval","volume":"81","author":"Shirley","year":"2021","journal-title":"Drugs"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1007\/s40265-016-0657-1","article-title":"Eteplirsen: First Global Approval","volume":"76","author":"Syed","year":"2016","journal-title":"Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1358\/dot.2020.56.8.3159186","article-title":"Golodirsen for Duchenne muscular dystrophy","volume":"56","author":"Anwar","year":"2020","journal-title":"Drugs Today"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1007\/s40265-020-01339-3","article-title":"Viltolarsen: First Approval","volume":"80","author":"Dhillon","year":"2020","journal-title":"Drugs"},{"key":"ref_32","unstructured":"Clemens, P.R., Previtera, M.L., Crozier, R.A., Magnus, L., Hoffman, E., Komaki, H., Aoki, Y., and Rao, V.K. (2024). Brogidirsen, an Investigational exon 44 Skipping Agent for the Treatment of Duchenne Muscular Dystrophy: Clinical Trial Design (Phase 2), Muscular Dystrophy Association National Office."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.nmd.2011.10.007","article-title":"Multiple exon skipping strategies to by-pass dystrophin mutations","volume":"22","author":"Adkin","year":"2012","journal-title":"Neuromuscul. Disord."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ana.24365","article-title":"Clinical phenotypes as predictors of the outcome of skipping around DMD exon 45","volume":"77","author":"Findlay","year":"2015","journal-title":"Ann. Neurol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Anwar, S., and Yokota, T. (2024). The Dysferlinopathies Conundrum: Clinical Spectra, Disease Mechanism and Genetic Approaches for Treatments. Biomolecules, 14.","DOI":"10.3390\/biom14030256"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.ebiom.2019.06.036","article-title":"Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases","volume":"45","author":"Tsoumpra","year":"2019","journal-title":"EBioMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.ymthe.2019.07.012","article-title":"Exons 45\u201355 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene","volume":"27","author":"Echigoya","year":"2019","journal-title":"Mol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ymthe.2020.05.024","article-title":"Correction of Three Prominent Mutations in Mouse and Human Models of Duchenne Muscular Dystrophy by Single-Cut Genome Editing","volume":"28","author":"Min","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/jhg.2016.28","article-title":"Deletion of exons 3\u22129 encompassing a mutational hot spot in the DMD gene presents an asymptomatic phenotype, indicating a target region for multiexon skipping therapy","volume":"61","author":"Nakamura","year":"2016","journal-title":"J. Hum. Genet."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/humu.20918","article-title":"Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations","volume":"30","author":"Fokkema","year":"2009","journal-title":"Hum. Mutat."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., and Bahal, R. (2020). Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med., 9.","DOI":"10.3390\/jcm9062004"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/(SICI)1099-1352(200001\/02)13:1<44::AID-JMR486>3.0.CO;2-6","article-title":"The conformations of locked nucleic acids (LNA)","volume":"13","author":"Petersen","year":"2000","journal-title":"J. Mol. Recognit."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"e202200169","DOI":"10.1002\/hlca.202200169","article-title":"The MOE Modification of RNA: Origins and Widescale Impact on the Oligonucleotide Therapeutics Field","volume":"106","author":"Hill","year":"2023","journal-title":"Helv. Chim. Acta"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100182","DOI":"10.1016\/j.crtox.2024.100182","article-title":"Comprehensive review of adverse reactions and toxicology in ASO-based therapies for Duchenne Muscular Dystrophy: From FDA-approved drugs to peptide-conjugated ASO","volume":"7","author":"Kohut","year":"2024","journal-title":"Curr. Res. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/978-1-59745-561-9_19","article-title":"Delivery of Phosphorodiamidate Morpholino Antisense Oligomers in Cancer Cells","volume":"542","author":"Devi","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/oli.1.1997.7.187","article-title":"Morpholino Antisense Oligomers: Design, Preparation, and Properties","volume":"7","author":"Summerton","year":"1997","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.omtn.2023.02.007","article-title":"Therapeutic phosphorodiamidate morpholino oligonucleotides: Physical properties, solution structures, and folding thermodynamics","volume":"31","author":"Maksudov","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/oli.1.1996.6.267","article-title":"Resistance of Morpholino Phosphorodiamidate Oligomers to Enzymatic Degradation","volume":"6","author":"Hudziak","year":"1996","journal-title":"Antisense Nucleic Acid Drug Dev."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.3390\/molecules14031304","article-title":"Gene Knockdowns in Adult Animals: PPMOs and Vivo-Morpholinos","volume":"14","author":"Moulton","year":"2009","journal-title":"Molecules"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-1-0716-2010-6_8","article-title":"Generation of Protein-Phosphorodiamidate Morpholino Oligomer Conjugates for Efficient Cellular Delivery via Anthrax Protective Antigen","volume":"2434","author":"Brock","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1089\/nat.2017.0682","article-title":"Development of Exon Skipping Therapies for Duchenne Muscular Dystrophy: A Critical Review and a Perspective on the Outstanding Issues","volume":"27","author":"Straub","year":"2017","journal-title":"Nucleic Acid Ther."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"6549","DOI":"10.1093\/nar\/gkw533","article-title":"Splice-switching antisense oligonucleotides as therapeutic drugs","volume":"44","author":"Havens","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14740338.2024.2447072","article-title":"Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?","volume":"24","author":"Tang","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e22187","DOI":"10.1002\/ddr.22187","article-title":"Unveiling the potential of antisense oligonucleotides: Mechanisms, therapies, and safety insights","volume":"85","year":"2024","journal-title":"Drug Dev. Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/humu.22758","article-title":"The TREAT-NMD DMD Global Database: Analysis of More than 7,000 Duchenne Muscular Dystrophy Mutations","volume":"36","author":"Bladen","year":"2015","journal-title":"Hum. Mutat."},{"key":"ref_56","unstructured":"Stahl, M., Zhu, Y., Goel, V., Leung, L., Tami, Y., Hardin, T., Etxaniz, U., Kovach, P., Herzog, J., and Hughes, S. (2025, June 16). AOC 1044 as a Novel Therapeutic Approach for DMD Patients Amenable to Exon 44 Skipping: EXPLORE44TM Phase 1\/2 Healthy Volunteer Data, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT05670730."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"14868","DOI":"10.1021\/acs.jmedchem.4c00803","article-title":"Structure\u2013Activity Relationship of Antibody\u2013Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody\u2013Phosphorodiamidate Morpholino Oligomer Conjugates for Drug Development","volume":"67","author":"Cochran","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Wilton-Clark, H., and Yokota, T. (2023). Recent Trends in Antisense Therapies for Duchenne Muscular Dystrophy. Pharmaceutics, 15.","DOI":"10.20944\/preprints202301.0139.v1"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"gkaf241","DOI":"10.1093\/nar\/gkaf241","article-title":"AOC 1044 induces exon 44 skipping and restores dystrophin protein in preclinical models of Duchenne muscular dystrophy","volume":"53","author":"Etxaniz","year":"2025","journal-title":"Nucleic Acids Res."},{"key":"ref_60","first-page":"1202","article-title":"Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy","volume":"11","author":"Nguyen","year":"2019","journal-title":"Am. J. Transl. Res."},{"key":"ref_61","unstructured":"Entrada Therapeutics (2025, June 16). Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44. Available online: www.entradatx.com."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1021\/acs.biochem.6b00226","article-title":"Discovery and Mechanism of Highly Efficient Cyclic Cell-Penetrating Peptides","volume":"55","author":"Qian","year":"2016","journal-title":"Biochemistry"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1021\/acschembio.0c00478","article-title":"Cell-Penetrating Peptides Escape the Endosome by Inducing Vesicle Budding and Collapse","volume":"15","author":"Sahni","year":"2020","journal-title":"ACS Chem. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"104441.304","DOI":"10.1016\/j.nmd.2024.07.313","article-title":"433P Therapeutic potential of ENTR-601-44, an Endosomal Escape Vehicle (EEVTM)\u2014Oligonucleotide Conjugate for the treatment of exon 44 skip amenable DMD","volume":"43","author":"Oldham","year":"2024","journal-title":"Neuromuscul. Disord."},{"key":"ref_65","unstructured":"Wahab, E. (2024). A Study to Investigate How ENTR-601-44 Behaves in the Body, the Safety and How Well Tolerated Different Increasing Amounts of the Drug ENTR-601-44 Are When Given to Healthy Male Volunteers, ISRCTN. Available online: http:\/\/isrctn.com\/."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"101901","DOI":"10.1016\/j.xcrm.2024.101901","article-title":"Phase 1\/2 trial of brogidirsen: Dual-targeting antisense oligonucleotides for exon 44 skipping in Duchenne muscular dystrophy","volume":"6","author":"Komaki","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_67","unstructured":"(2025, June 16). FDA Grants Breakthrough Therapy Designation to NS-089\/NCNP-02 for the Treatment of Duchenne Muscular Dystrophy. Nippon Shinyaku Co., Ltd. Available online: https:\/\/www.ncnp.go.jp\/topics\/2022\/20220317e.html."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.nmd.2022.07.239","article-title":"P.123 A Phase I\/II study of NS-089\/NCNP-02, Exon 44 skipping drug, in patients with Duchenne muscular dystrophy","volume":"32","author":"Komaki","year":"2022","journal-title":"Neuromuscul. Disord."},{"key":"ref_69","unstructured":"Bernardini, C. (2018). Designing Effective Antisense Oligonucleotides for Exon Skipping. Duchenne Muscular Dystrophy: Methods and Protocols, Humana Press. Available online: http:\/\/www.springer.com\/series\/7651."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"102034","DOI":"10.1016\/j.omtn.2023.102034","article-title":"Exon 44 skipping in Duchenne muscular dystrophy: NS-089\/NCNP-02, a dual-targeting antisense oligonucleotide","volume":"34","author":"Watanabe","year":"2023","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/acn3.51235","article-title":"Viltolarsen in Japanese Duchenne muscular dystrophy patients: A phase 1\/2 study","volume":"7","author":"Komaki","year":"2020","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/npr2.12335","article-title":"Systemic administration of the antisense oligonucleotide NS<-089\/NCNP-02 for skipping of exon 44 in patients with Duchenne muscular dystrophy: Study protocol for a phase I\/II clinical trial","volume":"43","author":"Ishizuka","year":"2023","journal-title":"Neuropsychopharmacol. Rep."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e3331","DOI":"10.1002\/brb3.3331","article-title":"Natural history of Duchenne muscular dystrophy in the United Kingdom: A descriptive study using the Clinical Practice Research Datalink","volume":"13","author":"Broomfield","year":"2023","journal-title":"Brain Behav."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Tulangekar, A., and Sztal, T.E. (2021). Inflammation in Duchenne Muscular Dystrophy\u2013Exploring the Role of Neutrophils in Muscle Damage and Regeneration. Biomedicines, 9.","DOI":"10.3390\/biomedicines9101366"},{"key":"ref_75","first-page":"S103","article-title":"P27 Three novel enhanced delivery Oligonucleotide candidates for Duchenne muscular dystrophy mediate high levels of exon 53, 45, and 44 skipping","volume":"33","author":"Holland","year":"2023","journal-title":"Neuromuscul. Disord."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Mellion, M., Larkindale, J., Lonkar, P., Goyal, J., Holland, A., Foy, J., Garg, B., Yu, S., Frank, A., and Abbott, C. (2025, June 25). PGN-EDO51, an Enhanced Delivery Oligonucleotide (EDO) for the Treatment of Duchenne Muscular Dystrophy (DMD): Results of a Phase 1 Study in Healthy Volunteers. American Academy of Neurology 2023 Annual Meeting. American Academy of Neurology. Available online: https:\/\/www.aan.com\/MSA\/Public\/Events\/AbstractDetails\/54382.","DOI":"10.1212\/WNL.0000000000203955"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"4477","DOI":"10.1038\/s41467-025-59494-8","article-title":"DG9 boosts PMO nuclear uptake and exon skipping to restore dystrophic muscle and cardiac function","volume":"16","author":"Shah","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Shang, M., Wu, Y., Wang, Y., Cai, Y., Jin, J., and Yang, Z. (2022). Dual antisense oligonucleotide targeting miR-21\/miR-155 synergize photodynamic therapy to treat triple-negative breast cancer and inhibit metastasis. Biomed. Pharmacother., 146.","DOI":"10.1016\/j.biopha.2021.112564"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1016\/j.bbamem.2010.02.012","article-title":"Morpholinos and their peptide conjugates: Therapeutic promise and challenge for Duchenne muscular dystrophy","volume":"1798","author":"Moulton","year":"2010","journal-title":"Biochim. et Biophys. Acta (BBA) Biomembr."},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Haque, U.S., and Yokota, T. (2023). Enhancing Antisense Oligonucleotide-Based Therapeutic Delivery with DG9, a Versatile Cell-Penetrating Peptide. Cells, 12.","DOI":"10.3390\/cells12192395"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3233\/JND-200483","article-title":"Clinical Phenotypes of DMD Exon 51 Skip Equivalent Deletions: A Systematic Review","volume":"7","author":"Waldrop","year":"2020","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"533","DOI":"10.2147\/DDDT.S97635","article-title":"Eteplirsen in the treatment of Duchenne muscular dystrophy","volume":"11","author":"Lim","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"e2112546119","DOI":"10.1073\/pnas.2112546119","article-title":"Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy","volume":"119","author":"Lim","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/humu.20428","article-title":"Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy","volume":"28","author":"Matsuo","year":"2007","journal-title":"Hum. Mutat."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/nrg1180","article-title":"Advances in Duchenne muscular dystrophy gene therapy","volume":"4","year":"2003","journal-title":"Nat. Rev. Genet."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1093\/brain\/awr291","article-title":"Dystrophin quantification and clinical correlations in Becker muscular dystrophy: Implications for clinical trials","volume":"134","author":"Anthony","year":"2011","journal-title":"Brain"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s40265-020-01267-2","article-title":"Golodirsen: First Approval","volume":"80","author":"Heo","year":"2020","journal-title":"Drugs"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.omtn.2017.06.013","article-title":"Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse Model","volume":"8","author":"Relizani","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3233\/JND-210643","article-title":"Open-Label Evaluation of Eteplirsen in Patients with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping: PROMOVI Trial","volume":"8","author":"McDonald","year":"2021","journal-title":"J. Neuromuscul. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1089\/nat.2021.0043","article-title":"Long-Term Safety and Efficacy Data of Golodirsen in Ambulatory Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping: A First-in-human, Multicenter, Two-Part, Open-Label, Phase 1\/2 Trial","volume":"32","author":"Servais","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1080\/13543784.2024.2313105","article-title":"Duchenne muscular dystrophy: Promising early-stage clinical trials to watch","volume":"33","author":"Tang","year":"2024","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"S204","DOI":"10.1016\/j.jval.2021.04.1023","article-title":"PRO38 Twenty Years of Clinical Trials in Duchenne Muscular Dystrophy: A Low Clinical Drug Development Success","volume":"24","author":"Dovari","year":"2021","journal-title":"Value Health"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1056\/NEJMoa2307798","article-title":"Death after High-Dose rAAV9 Gene Therapy in a Patient with Duchenne\u2019s Muscular Dystrophy","volume":"389","author":"Lek","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1056\/NEJMc2212912","article-title":"Dystrophin Immunity after Gene Therapy for Duchenne\u2019s Muscular Dystrophy","volume":"388","author":"Belluscio","year":"2023","journal-title":"N. Engl. J. Med."}],"container-title":["Genes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/7\/777\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:02:02Z","timestamp":1760032922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4425\/16\/7\/777"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,30]]},"references-count":94,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,7]]}},"alternative-id":["genes16070777"],"URL":"https:\/\/doi.org\/10.3390\/genes16070777","relation":{},"ISSN":["2073-4425"],"issn-type":[{"value":"2073-4425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,30]]}}}